Post vaccine syndrome

Post-Vaccination Syndrome:

A Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization

https://www.medrxiv.org/content/10.1101/2023.11.09.23298266v1.full.pdf

Yale Listen to Immune, Symptom and Treatment Experiences Now (LISTEN) Study (online)

https://medicine.yale.edu/ycci/listen-study/

LISTEN study, approved by Yale University Institutional Review Board

Introduction

A chronic post-vaccination syndrome (PVS) after covid-19 vaccination has been reported but has yet to be well characterized.

A chronic syndrome with symptoms that begin soon after vaccination

Methods

People who joined, May 2022 to July 2023

N = 241 individuals, (211 from the US)

aged 18 and older,

who self-reported PVS after covid-19 vaccination,

Deep immune profiling is used for some individuals

Results

Median age of participants, 46 years

Among participants with PVS

127 (55%) had received BNT162b2 [Pfizer-BioNTech]

86 (37%) received the mRNA-1273 [Moderna]

Time from index vaccination to symptom onset

Median time, 3 days (IQR: 1 day to 8 days).

Time from vaccination to symptom survey completion

595 days (IQR: 417 to 661 days)

Median Euro-QoL visual analogue scale score was 50 (IQR: 39 to 70).

The five most common symptoms

Exercise intolerance (71%)

Excessive fatigue (69%)

Numbness (63%)

Brain fog (63%)

Neuropathy (63%)

In the week before survey completion

(Experienced at least once in the week)

Feeling unease (93%)

Fearfulness (82%)

Overwhelmed by worries (81%)

Feelings of helplessness (80%)

Anxiety (76%)

Depression (76%)

Hopelessness (72%)

Worthlessness (49%)

Concerns related to living situations and food security were also prominent.

Symptom Severity

When asked to quantify symptom severity on their worst days,

(0 representing a trivial illness and 100 unbearable condition)

Participants reported a median severity of 80

Interventions to treat their condition

Participants reported a median of 20 (IQR: 13 to 30).

Oral steroids, 116 (48% participants)

Gabapentin, 61 (25%)

Low-dose naltrexone, 48 (20%)

I, 44 (18%)

Propranolol, 27 (11%)

Bronchodilators, 26 (11%)

More than 500 additional treatments were reported by participants

Limiting exercise or exertion

Quitting alcohol or caffeine

Hydration and increasing salt intake

Intermittent fasting

Conclusions

In this study, individuals who reported PVS after covid-19 vaccination had low health status,

high symptom burden,

and high psychosocial stress,

despite trying many treatments.

There is a need for continued investigation to understand and treat this condition.

Looks like you can join, Kindred study

Kindred is a community of patients, working with researchers to power more useful, impactful progress.

https://www.kindred.hugo.health/research/listen-study

https://kindredapp.hugo.health/auth/login?ref=%2F